Filing Flows › Adaptive Biotechnologies (ADPT) › How it makes money
How Adaptive Biotechnologies (ADPT) makes money
Adaptive Biotechnologies (ADPT) made $83.9M of revenue in the third quarter 2026 (Q3 2026), -11% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $83.9M | 100.0% |
| Operating cash flow | $9.6M | 11.4% |
| Free cash flow | $7.7M | 9.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $83.9M | -11% |
| Q2 2026 | $71.6M | +22% |
| Q1 2026 | $70.9M | +35% |
| Q4 2025 | $71.7M | +51% |
| Q3 2025 | $94.0M | +102% |
| Q2 2025 | $58.9M | +36% |
| Q1 2025 | $52.4M | +25% |
From Adaptive Biotechnologies' 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Adaptive Biotechnologies make money?
Adaptive Biotechnologies (ADPT) made $83.9M of revenue in the third quarter 2026 (Q3 2026), -11% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.